Voyager Therapeutics, Inc.
VYGR
$3.46
$0.10423.10%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -7.61% | 10.05% | -281.32% | 10.82% | 10.49% |
Total Depreciation and Amortization | 5.03% | 0.30% | -10.69% | -18.68% | 16.39% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 15.79% | 74.02% | 44.25% | -73.74% | 115.95% |
Change in Net Operating Assets | 53.53% | -170.78% | 177.20% | 24.90% | -143.52% |
Cash from Operations | 12.23% | -160.82% | 48.05% | 11.44% | -153.74% |
Capital Expenditure | -67.93% | -324.52% | 39.92% | 73.32% | 54.83% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -92.74% | 254.76% | -141.86% | 284.73% | 62.76% |
Cash from Investing | -95.31% | 251.46% | -142.27% | 279.04% | 62.58% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 525.61% | -85.71% | 4,000.00% | -97.55% | -99.49% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 525.61% | -85.71% | 4,000.00% | -97.55% | -99.49% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -1,009.53% | 108.23% | -213.08% | 154.36% | -188.61% |